anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aim of this study is to assess the clinical efficacy of 445 nm Diode laser as an adjunct to Kirkland flap surgery in management of periodontitis. Type of study is a Split mouth clinical trial in which a total of 13 patients were recruited based on specific inclusion and exclusion criteria. In each participant, random allocation of selected sites into test and control in contralateral quadrants was done. Clinical parameters such as probing depth and clinical attachment loss was measured in control and test sites using occlusal stents. Flap surgery was carried out 6 weeks after phase I therapy and the selected contralateral sites with a probing depth of > 5mm were subjected to surgical therapy. In a test quadrant, 445 nm diode laser with a power of 0.8 W, CW mode, 320 µm fiber, in non-contact mode was used as an adjunct to flap surgery. Primary outcome variable assessed was change in PPD between baseline, pre-operative, 1-, 3- and 6-months post-surgery. Secondary outcomes variables assessed were Clinical attachment loss at baseline, pre-operative, 1, 3 and 6 months, visual analog scale at days 3 and 7 and patient satisfaction index at day 7 post surgery. Surgery for the second site (Test/control) in the contralateral quadrants was performed 1 week after the first surgery. A higher reduction in probing depth and gain in CAL was observed in test site at 1, 3 and 6 months follow up amongst all the included participants. VAS score was lower at the test site as compared to the control sites. PSI scores were similar in both the sites. The adjunctive use of 445nm diode laser to surgical periodontal therapy contributed to improved short term clinical outcomes as assessed at the end of 6 months post- surgery. VAS score indicative of post -surgical discomfort were also lower for the laser treated sites. Hence adjunctive use of laser (445 nm wavelength) can be recommended for achieving more predictable clinical outcomes.
Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. At the end of follow up, the control arm will receive similar services from POH to what the intervention arm received during the intervention, regardless POH eligibility criteria (6 months of DM-tailored food support to meet 67% of their daily requirements, video recording of the 4 CHEFS-DM education classes, and access to a POH dietitian at their request).
The systematic review aims to answer the PICOS question: "Are the autologous platelet concentrates (APCs) an effective strategy in prevention and/or treatment of patients at risk of/affected by medication-related osteonecrosis of the jaws (MRONJ)?". A literature search was conducted via PubMed, MEDLINE, EMBASE, and CINAHL (January 2006 - September 2023). 30 articles were included, evaluating preventive (n = 8*) and treatment strategies (n = 23*). The risk of bias and quality of studies were assessed utilising ROB-2, ROBIN-1 and GRADE criteria. Meta-analysis was undertaken for eligible studies. The application of APCs demonstrated a statistically significant effectiveness in prevention of MRONJ in 86.13% (p < 0.001) but failed to achieve the same level of certainty in treatment of established MRONJ in 83.4% (p = 0.08). High levels of bias were identified; thus, the results should be interpreted with caution. More high quality prospective randomised controlled trials are needed to further evaluate the effectiveness of APCs in management of MRONJ.
Use the lowest dose of ALVAIZ to achieve and maintain a hematologic response. Dose adjustments are based upon the platelet count. Hematologic response requires dose titration, generally up to 108 mg, and may take up to 16 weeks after starting ALVAIZ [see Clinical Studies (14.3)].

Initial Dose Regimen: Initiate ALVAIZ at a dose of 36 mg orally once daily.

For patients with severe aplastic anemia of East-/Southeast-Asian ancestry or those with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, C), initiate ALVAIZ at a reduced dose of 18 mg once daily [see Use in Specific Populations (8.6, 8.7), Clinical Pharmacology (12.3)].

Monitoring and Dose Adjustment: Adjust the dose of ALVAIZ in 36-mg increments every 2 weeks as necessary to achieve the target platelet count greater than or equal to 50 x 109/L as necessary. Do not exceed a dose of 108 mg daily. Monitor clinical hematology and liver tests regularly throughout therapy with ALVAIZ and modify the dosage regimen of ALVAIZ based on platelet counts as outlined in Table 3.

For patients who achieve tri-lineage response, including transfusion independence, lasting at least 8 weeks: the dose of ALVAIZ may be reduced by 50% [see Clinical Studies (14.3)]. If counts remain stable after 8 weeks at the reduced dose, then discontinue ALVAIZ and monitor blood counts. If platelet counts drop to less than 30 x 109/L, hemoglobin to less than 9 g/dL, or absolute neutrophil count (ANC) to less than 0.5 x 109/L, ALVAIZ may be reinitiated at the previous effective dose.

Discontinuation: If no hematologic response has occurred after 16 weeks of therapy with ALVAIZ, discontinue therapy. If new cytogenetic abnormalities are observed, consider discontinuation of ALVAIZ [see Adverse Reactions (6.1)]. Excessive platelet count responses (as outlined in Table 3) or important liver test abnormalities also necessitate discontinuation of ALVAIZ [see Warnings and Precautions (5.2)].
Background: The health measures imposed by COVID-19 on workplaces created adverse communication settings. Our cross-sectional study aimed to document the nature and severity of the vocal difficulties experienced by educational professionals a few weeks after the implementation of health measures in schools and early childhood settings in Quebec, Canada while teaching in class.Methods: To this end, we conducted a self-report survey containing nine close-ended questions and one open-ended question regarding self-reported vocal difficulties and the implementation of health measures. The survey was answered by 194 educational professionals in October 2020.Results: Since the introduction of the health measures, respondents reported often or always: having difficulty making themselves heard (66.5%), needing to strain their voice (68.1%), having throat pain after work (38.1%), and being concerned about their vocal health (25.2%). 35.6% perceived that their voice changed moderately or a lot and 75.3% did not feel equipped to take care of their vocal health. Fisher's exact tests revealed the difficulties overall were more present in women (p < 0.05).Discussion: The qualitative analysis of open-ended question answers shows a circular process at play, where the vocal responses to the COVID-19-induced communication barriers contribute to creating more problematic communication settings, thus increasing the challenges for vocal health. Better equipping the professionals to take care of their vocal health by developing resources in their professional settings to help them face vocal challenges in both every day as well as extreme situations, should be a priority.
OBJECTIVES: Adiponectin plays an important role in carbohydrate and lipid metabolism. However, the evidence regarding the association between adiponectin and diabetes mellitus in obese dogs is sparse. The aim of this study is to investigate the associations of adiponectin with the risk of diabetes mellitus in obese dogs on the basis of a prospective cohort study.
MATERIALS AND METHODS: Serum adiponectin levels in obese dogs recruited from three small animal hospitals between 2015 and 2018 were measured by ELISA. Electronic health records were used to record the incidence of diabetes mellitus during follow-up for 3 years.
RESULTS: A total of 862 dogs were included. Amongst the 862 dogs, 51 developed diabetes. Adiponectin levels were associated with diabetes mellitus after adjusting for sex, age, breed, exercise, body condition score, fasting plasma glucose, serum triglyceride and total cholesterol. When adjusting for sex, age, breed, exercise, body condition score, fasting plasma glucose, serum triglyceride and total cholesterol, the adjusted hazard ratios were 7.83 (95% confidence interval: 2.67 to 30.13) in the lowest adiponectin group and 1.96 (95% CI: 1.10 to 8.55) in the medium adiponectin group relative to that in the highest adiponectin group. The area under a curve of adiponectin's Receiver operating characteristic curve was 0.81 (95% CI: 0.76 to 0.86).
CLINICAL SIGNIFICANCE: Low adiponectin is associated with diabetes mellitus and has a high risk of incident diabetes mellitus, implying the potential of adiponectin as a predictive biomarker of diabetes mellitus in obese dogs.
A method for manufacturing citri reticulatae pericarpium using lemon peel is used to improve the economic value of the lemon peel. The method includes simmering a lemon peel sample in an aqueous citric acid solution for a time period ranging from 30 minutes to 50 minutes to obtain the lemon peel sample with less bitterness. The lemon peel sample with less bitterness is simmered in an aqueous sodium bicarbonate solution for a time period ranging from 5 minutes to 30 minutes to obtain the lemon peel sample with improved taste. The lemon peel sampe with improved taste is soaked in an aqueous glycyrrhizin solution for a time period ranging from 60 minutes to 240 minutes to obtain the lemon peel sample with more sweetness. The lemon peel sample with more sweetness is stored in an environment with a temperature ranging from 50 DEG C to 95 DEG C and a humidity ranging from 65% to 99% for a time period ranging from 1 days to 7 days to obtain an aging lemon peel sample. Finally, the aging lemon peel sample is dried to obtain the citri reticulatae pericarpium with a water content ranging from 1% to 20%.
The invention provides application of pinoresinol in preparing a medicament for inhibiting thrombosis, and relates to the field of chemical medicaments. Specifically provides an application of the compound shown in the formula I, or a salt, a solvate, a hydrate or a prodrug thereof in preparing a medicament for inhibiting thrombosis. The compound represented by the formula I is preferably pinoresinol. The research of the invention finds that the compound pinoresinol extracted from the yellow clover can be used for inhibiting vasoconstriction and has obvious vasodilation effect. At the same time, the compound pinoresinol has inhibitory effect on thrombosis, and low dose of pinoresinol inhibitsThe effect of thrombosis is better than that of high dose, the thrombosis inhibition rate is as high as 76.92%, the dosage of the medicine is reduced while the excellent effect of inhibiting thrombosis is obtained, and the safety of the medicine use is improved. The compound pinoresinol can be used for preparing medicines for inhibiting thrombosis and preventing or treating thromboembolic diseases, and has good application prospect.
PROBLEM TO BE SOLVED: To perfectly sterilize micro-organisms in a composition inexpensively, safely, and efficiently without damaging quality of the composition containing a surface active agent, by heating and treating the composition containing the surface active agent at a specific temperature and for a specific period, under existence of a specific ratio of anticeptic. SOLUTION: A composition containing a surface active agent which contains 0.1-2 wt.% anticeptic is guided into a storage tank 3, and then it is transferred to a heat exchanger 4 for heating through a pump 13. A heating medium is circulated to the heat exchanger 4 for heating from hot-water tank 1 for heating through a pump 11 in order to heat the composition containing the surface active agent. The composition containing the surface active agent in the heat exchanger 4 for heating is heated at 45-70 deg.C and is treated by a sterilization pipe 6 for only 15-600 sec. While, the sterilized composition containing the surface active agent is transferred to a heat exchanger 5 for cooling, and then is transferred to a filling machine 7.  A cooling medium is circulated to the heat exchanger 5 for cooling from cold-water tank 2 for cooling using a pump 12 to cool the composition containing the surface active agent.
Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
<P>PROBLEM TO BE SOLVED: To provide a nutrition dispenser (100).  <P>SOLUTION: The invention relates to the nutrition dispenser (100) producing doses of nutrition and/or medication and to the method for producing the doses with the help of the nutrition dispenser. A database mechanism is linked to the nutrition dispenser (100), and further, the nutrition dispenser typically comprises the user interface (102) for feeding at least the information of the user, and rooms (108) for storing different nutrition and/or medical substances. In addition, the nutrition dispenser is arranged to define the optimal dose of nutrition and/or medication intended for the person consuming the dose, and its ingredients, amounts and proportions of ingredients at least partly with the help of the database mechanism. The nutrition dispenser can further comprise equipment (110) for measuring out the defined nutrients.  <P>COPYRIGHT: (C)2011,JPO&INPIT
All non-consecutive participants operated on in a hospital were included, both those who, based on a protocol prepared by the investigators unit, were classified as having no risk of developing complications, low risk or high risk. Partfipants classified as low and high risk, after their consent to participate in the study, entered to form part of it. This participanta were classified before surgery according to the risk factors of themselves and of the procedure, and those at risk were randomized to treatment with a negative pressure therapy dressing or no treatment, and a cure was performed with a conventional dressing. The participants classified as not at risk of complications were not included in the study. In this way the investigators tried to analyze if the intervention with the negative pressure therapy dressing reduced the complications of the surgical site.The primary objective was to analyze the reduction of surgical site infections in participants treated with negative pressure therapy compared to those treated with conventional dressing. As secondary objectives the investigators proposed to measure other complications in both groups and the hospital stay.
Our research question is: Is hydroxychloroquine an efficacious medicine to use in patients with chronic urticaria? Answering this question should help allergists treat chronic urticaria with a more evidence based approach. To date there has one been one prospective trial evaluating hydroxychloroquine in hives, and although it showed a trend towards efficacy (0.05\<p\<0.10), it was not statistically significant. There have been case series, and anecdotal reports which seem to demonstrate efficacy of chloroquine in chronic urticaria. Because of these reports hydroxychloroquine is often the first medication used in patients with chronic hives that are refractory to standard therapy of antihistamines. We believe an evidence based answer to this question will be an important step towards improved treatment of this disease.

We plan to ascertain the efficacy of hydroxychloroquine by completing a randomized double blinded placebo controlled study of treatment in patients with chronic urticaria. We will be measuring an Urticarial Score to evaluate hive symptoms. We will be measuring them at baseline, and at the end of the study to note change in drug vs placebo.
Participants will undergo 20 sessions of home-based tDCS over the prefrontal cortex and tACS over the left angular gyrus.These sessions will take place five times a week for four weeks, with one daily stimulation session of no more than 20 minutes. The participant's home will be the setting for the completion of the brain stimulation intervention, which will be delivered by trained caregivers/study companions/administrators.
Outpatient local anaesthesic (LA) hysteroscopic intrauterine therapeutic interventions such as endometrial ablation have gained wider acceptance in the last decade. However, pain experienced during these procedures can be a disincentive and is the commonest reason for the use of escalating levels of analgesia post procedure, which results in prolongation of hospital stay and recovery. Various methods of LA have been studied including intrauterine topical lignocaine or cervical block using topical lignocaine, paracervical block or intracervical block. However, a single site block individually may not be sufficient to control the pain completely due to inability of the one site block to affect the sensitivity of the whole uterus, as the uterine fundus is effectively still unanaesthetised. This may be due to the uterus receiving complex innervations from different nerve routes such as the uterovaginal plexus, the Frankenhauser nerve plexuses, parasympathetic ganglia and the thoracic nerve.

Therefore, it seems logical to use a direct cervical block to block the sensation through uterovaginal plexus and use an additional deep myometrial block adjacent to each cornua to directly block the thoracic nerve supply. To date, only one small observational study has looked at the effect of such a combined block in relieving pain during outpatient hysteroscopic procedures. Therefore, we propose to undertake a double blind randomised controlled trial to address this question by comparing effectiveness of a standard direct cervical block and intrauterine cornual block (ICOB) versus a direct cervical block and a normal saline intrauterine cornual injection (control).
<P>PROBLEM TO BE SOLVED: To obtain a detergent composition that contains nisin and has excellent storage stability.  <P>SOLUTION: The detergent composition comprises a surfactant selected from a proper screening system, namely, an effective cleaning amount of a surfactant composed of (A) an effective antibacterial amount of nisin and (B) one or more kinds of components not to reduce nisin activity. For example, an alkyl glycoside may be cited as the surfactant component not to reduce nisin activity to be used in the detergent composition. Nisin is found to be stable in an acidic range, many surfactants secure stability in an acidic range. A detergent having low skin irritation and excellent storage stability of nisin in a solution state adjusted to a concentration useful for cleaning is preferable as the detergent.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
Extreme weather events, such as severe droughts, pose a threat to the sustainability of beef cattle by limiting the growth and development of forage plants and reducing the available pasture for animals. Thus, the search for forage species that are more tolerant and adapted to soil water deficit conditions is an important strategy to improve food supply. In this study, we propose utilizing the mathematical concept of the Manhattan distance to assess the variations in the morphological variables of tropical forage grasses under water-limited conditions. This study aimed to select genotypes of tropical forage grasses under different water stress levels (moderate or severe) at this distance and the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). Nine varieties from five species were examined. Forage grasses were grown in 12-L pots under three soil irrigation regimes [100% pot capacity-PC (well-irrigated control), 60% PC (moderate drought stress), and 25% PC (severe drought stress)] with four replicates. Drought stress treatments were applied for 25 days during the forage grass tillering and stalk elongation phases. After exposure to drought stress, the growth and morphological traits of forage plants were evaluated. The results show that the use of the Manhattan distance combined with TOPSIS helps in the genotypic selection of more stable tropical forage grass varieties when comparing plants exposed to moderate and severe drought conditions in relation to the nonstressful environment (control). The 'ADR 300', 'Pojuca', 'Marandu', and 'Xaraés' varieties show greater stability when grown in a greenhouse and subjected to water stress environments. The selected forage varieties can be used as parents in plant breeding programs, allowing us to obtain new drought-resistant genotypes.
PURPOSE: A composition containing a collagen triple helix repeat containing 1 inhibitor is provided to suppress cancer metastasis, and a screening method is provided to efficiently identify a drug for suppressing the cancer metastasis. CONSTITUTION: A pharmaceutical composition for suppressing cancer metastasis comprises a gene expression inhibitor of collagen triple helix repeat containing 1(CTHRC1) or a protein expression inhibitor as active ingredients. A screening method for suppressing the cancer metastasis comprises the following steps. CTHRC1 is inserted to cancer cells. The level of the expression of phosphorylated extracellular signal-regulated kinases in the cancer cells is measured. The level of the expression of phosphorylated extracellular signal-regulated kinases is measured after treating the cancer cells with the candidate for suppressing the cancer metastasis. If the level of the expression after treating the cancer cells with the candidate is lower than the level of the expression without the treatment with the candidate, then the candidate is selected for an inhibitor for the cancer metastasis.
Certain embodiments of the present invention provide a system for medical report dictation including a database component, a voice recognition component, and a user interface component. The database component is adapted to store a plurality of available templates. Each of the plurality of available templates is associated with a template cue. Each template cue includes a list of elements. The voice recognition component is adapted to convert a voice data input to a transcription data output. The user interface component is adapted to receive voice data from a user related to an image and the user interface component is adapted to present a visual indicator to the user. The visual indicator is based on a template cue associated with a template selected from the plurality of available templates. The user interface utilizes the voice recognition component to update the visual indicator.